Professor Sander van Deventer Appointed to Supervisory Board of AMT

CFO Piers Morgan Appointed to Management Board

AMSTERDAM, The Netherlands, May 6, 2010 - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field
of human gene therapy, announced today that, at the Annual General Meeting
(AGM) of the Company Professor Sander van Deventer has been appointed to the
Supervisory Board.

Professor van Deventer is one of AMT's co-founders. He was
Professor and Head of the Department of Experimental Medicine, Chairman at
the Department of Gastroenterology of the AMC from 2002 to 2004, and
subsequently Professor of Experimental Medicine at the University of
Amsterdam Medical School until 2008. He has over 15 years experience in
biotechnology product development. He is the author of more than 350
scientific articles in peer-reviewed journals and serves as an advisor to
regulatory authorities including the EMA and FDA.

Professor van Deventer served on the Management Board of AMT
as Chief Scientific Officer until February 2009, and temporarily also as
Chief Executive Officer from February - October 2009. He currently chairs the
Scientific Advisory Board of AMT. He is also a partner of Forbion Capital, a
shareholder in the Company, and Professor of Translational Gastroenterology
at the Leiden University Medical Center (LUMC).

As a result of Professor van Deventer's previous position as a
member of the Management Board, among others, he is not independent within
the meaning of provision III.2.2 of the Dutch Corporate Governance Code.

Also at the Annual General Meeting Mr Piers Morgan, CFO, was
appointed to the Management Board and Mr Alexander Ribbink retired as a
member of the Supervisory Board. All resolutions proposed to the Annual
General Meeting, as set out in the Notice of General Meeting dated April 12,
2010, were approved unanimously.

Jörn Aldag CEO of AMT said:

"AMT is delighted that Sander van Deventer is joining the
Supervisory Board. His contributions to the continued development of the
Company have been and will be extremely valuable. We would also like to thank
Alexander Ribbink for the support he has given to the Company during a period
of significant progress and change for AMT."

About Amsterdam Molecular Therapeutics

AMT, founded in 1998 and based in Amsterdam, is a leader in
the development of human gene based therapies. Using AAV as the delivery
vehicle of choice for therapeutic genes, the company has been able to design
and validate what is probably the first stable and scalable AAV production
platform. This safe and efficacious proprietary platform offers a unique
manufacturing capability which can be applied to a large number of rare
(orphan) diseases that are caused by one faulty gene. Currently, AMT has a
product pipeline with several AAV-based gene therapy products in LPLD,
Hemophilia B, DMD, Acute Intermittent Porphyria and Parkinson's Disease at
different stages of research or development.

Certain statements in this press release are "forward-looking
statements" including those that refer to management's plans and expectations
for future operations, prospects and financial condition. Words such as
"strategy," "expects," "plans," "anticipates," "believes," "will,"
"continues," "estimates," "intends," "projects," "goals," "targets" and other
words of similar meaning are intended to identify such forward-looking
statements. Such statements are based on the current expectations of the
management of Amsterdam Molecular Therapeutics only. Undue reliance should
not be placed on these statements because, by their nature, they are subject
to known and unknown risks and can be affected by factors that are beyond the
control of AMT. Actual results could differ materially from current
expectations due to a number of factors and uncertainties affecting AMT's
business, including, but not limited to, the timely commencement and success
of AMT's clinical trials and research endeavors, delays in receiving U.S.
Food and Drug Administration or other regulatory approvals (i.e. EMA, Health
Canada), market acceptance of AMT's products, effectiveness of AMT's
marketing and sales efforts, development of competing therapies and/or
technologies, the terms of any future strategic alliances, the need for
additional capital, the inability to obtain, or meet, conditions imposed for
required governmental and regulatory approvals and consents. AMT expressly
disclaims any intent or obligation to update these forward-looking statements
except as required by law. For a more detailed description of the risk
factors and uncertainties affecting AMT, refer to the prospectus of AMT's
initial public offering on June 20, 2007, and AMT's public announcements made
from time to time.

PRN NLD

For further enquiries: Jörn Aldag CEO, Tel: +31(0)20-566-7394, Tel: +31(0)6-8195-3060, j.aldag at amtbiopharma.com